EVOLVE Short DAPT Begins Enrollment
Evaluation of reduced DAPT duration with next generation bioabsorbable polymer DES
In the recent results of the DAPT study, PI’s Dr. Laura Mauri and Dr. Dean Kereiakes have demonstrated that for select patients receiving bare or permanent polymer DES, longer durations of DAPT (>12 months) may be favored for ST and MI. Remaining on DAPT past 12 months may be problematic for patients at high risk for bleeding and may have side effects for the patient. With the introduction of bioabsorbable polymer DES, an advantage in intravascular healing may be provided such that certain patients can safely reduce their DAPT duration. As principal investigator of the recently approved EVOLVE Short DAPT trial, Dr. Mauri will be evaluating a novel, bioabsorbable polymer DES, SYNERGY, with 3 month DAPT in patients at high risk for bleeding.
Dr. Mauri’s EVOLVE Short DAPT Announcement
“Reducing DAPT duration post-stenting may be desirable, either for known or unanticipated reasons. However, supporting clinical evidence for reducing DAPT duration is limited and further research is required to safely make changes to the current DAPT duration paradigm. The EVOLVE Short DAPT study was designed to evaluate the safety of a planned DAPT duration of 3 months with the SYNERGY Stent in patients at high risk for bleeding. This study is the first prospective, global evaluation of 3 month DAPT duration in patients receiving a bioabsorbable polymer DES. SYNERGY’s unique design features may provide additional healing benefits such that the ischemic risks of discontinuing DAPT at 3 months are acceptable for patients at high risk for bleeding. I am pleased to say that the first patient was enrolled on February 16th by the Lindner Center for Research and Education at Christ Hospital. "